Dr. Richardson on the Use of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Kristin J. Richardson, MD
Published: Friday, Apr 05, 2019



Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

CDK4/6 inhibitors have had a dramatic impact on the management of patients with metastatic HR-positive, HER2- breast cancer. Currently, all 3 agents
SELECTED
LANGUAGE


Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

CDK4/6 inhibitors have had a dramatic impact on the management of patients with metastatic HR-positive, HER2- breast cancer. Currently, all 3 agents



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x